Sonnet biotherapeutics announces webcast to discuss interim data from the company's phase 1 dose-escalation trials of son-1010 on november 2, 2022

Princeton, nj / accesswire / november 1, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share initial clinical data from its sb101 clinical study with son-1010 in oncology patients (nct05352750) and its sb102 clinical study with son-1010 in healthy volunteers (nct05408572) on wednesday, november 2, 2022 at 8:30 am et. webcast presenters will include:richard kenney, m.d.
SONN Ratings Summary
SONN Quant Ranking